BioInvent International AB - Company Profile
Powered by 
All the sales intelligence you need on BioInvent International AB in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BioInvent International AB fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BioInvent International AB.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioInvent International AB Catalyst Calendar
Proactively evaluate BioInvent International AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of BioInvent International AB Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 30 Jun 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 30 Jun 2020 | Phase I/II Trial Results | BioInvent International AB; Blood Cancer UK Ltd; Cancer Research UK | BINV | BI-1206 | Oncology | B-Cell Chronic Lymphocytic Leukemia; Blood Cancer; Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Leukemia; Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed Chronic Lymphocytic Leukemia (CLL); Unspecified B-Cell Lymphomas; Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) | Company Press Release |
| 30 Jun 2020 | IND Filing (US) | BioInvent International AB | BINV | BT-001 | Oncology | Solid Tumor | Company Press Release |
| 01 Jun 2020 | Phase I/II Trial Initiation | BioInvent International AB; Merck & Co Inc; Sarah Cannon Research Institute LLC | BINV; MRK | BI-1206; pembrolizumab | Oncology | Hematological Tumor; Metastatic Melanoma; Metastatic Uveal Melanoma; Non-Small Cell Lung Cancer; Sarcomas; Solid Tumor | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer